congress
presentations

Anxiety and Depression Association of America (ADAA) 2024 Conference

Boston, MA
April 11-14, 2024

PDF screenshot

AXS-05 | Major Depressive Disorder

Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data from 3 Clinical Trials

view/download

Dr. Craig Chepke, MD, DFAPA describes the “Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data from 3 Clinical Trials” ADAA 2024 poster

view

PDF screenshot

AXS-05 | Major Depressive Disorder

Impact of AXS-05, an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder

view/download

Dr. Roger S McIntyre, MD, FRCPC describes the “Impact of AXS-05, an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder” ADAA 2024 poster

view

This site is intended for registered attendees of the respective Congress.
This site contains scientific presentations on investigational products and/or investigational uses of approved products for Axsome or its partners sponsored studies.
The safety and efficacy of investigational products and/or investigational uses of approved products has not been established and such investigational products/uses have not and may not be approved for marketing by any health authority.
Marketing authorization, approval status, and prescribing information for approved products varies by country. Please seek further details from the health authority in your country such as approved product labeling.

AXSOME and its logos are trademarks or registered trademarks of Axsome Therapeutics, Inc. or its affiliates. Other trademarks are property of their respective owners.

© 2023 Axsome Therapeutics, Inc. All rights reserved. One World Trade Center, 22nd Floor, New York, NY 10007 info@axsome.com